National Cancer Institute; Notice of Closed Meeting, 10540 [06-1879]
Download as PDF
<![CDATA[
10540
Federal Register / Vol. 71, No. 40 / Wednesday, March 1, 2006 / Notices
needs assessments are continually
absent.’’ (USAID 2001: The Use and
Effect of Distance Education in
Healthcare: What Do We Know?
Operations Research Issue Paper 2) This
survey will address that issue.
The survey is based on
recommendations received from current
international drug abuse researchers and
NIDA grantees. It is designed to be brief
(2 pages) and succinct, asking
respondents to prioritize their
educational needs. The questions have
been previously tested with persons
who speak English as a second
language. Total time to complete the
survey is less than five minutes. The
survey will cover the following
elements: (1) Respondent background,
including availability of educational
technologies, (2) Educational needs,
including a ranking of 10 proposed
topics in drug abuse education, and (3)
Collaborative needs, including an
estimate of the value of online tools for
research collaboration. The survey will
not collect name, address, or other
identifying information. Frequency of
Response: This project will be
conducted once. Affected Public:
International drug abuse researchers
who are currently affiliated with or wish
Estimated
number of
respondents
Drug abuse researcher respondents
to be affiliated with the U.S. drug abuse
research community. Type of
Respondents/Drug Abuse Researchers:
physicians, scientists, mental health
workers, and scientists-in-training. The
reporting burden is as follows:
Estimated Total Annual Number of
Respondents: 250; Estimated Number of
Responses per Respondent: 1; Average
Burden Hours per Response: 0.09.
Estimated Total Annual Burden Hours
Requested: 22.5. There are no Capital
Costs to report. There are no Operating
or Maintenance Costs to report. The
estimated annualized burden is
summarized below.
Estimated
number of
responses per
respondent
Average
burden hours
per response
Estimated total
burden hours
Physicians ........................................................................................................
PhD Scientists .................................................................................................
Mental Health/Drug Abuse Professionals ........................................................
Scientists-in-Training .......................................................................................
100
70
40
40
1
1
1
1
0.09
0.09
0.09
0.09
9.0
6.3
3.6
3.6
Annualized Totals ............................................................................................
250
1
0.09
22.5
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(2) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (3) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
To
request more information on the
proposed project or to obtain a copy of
the information collection plans, contact
Dale Weiss, Project Officer, National
Institute on Drug Abuse, 6001 Executive
Boulevard, Room 5274, Bethesda, MD
20892, or call non-toll-free number 301–
402–6683; fax 301–443–9127; or by email to dweiss@nida.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
wwhite on PROD1PC61 with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Aug<31>2005
18:25 Feb 28, 2006
Jkt 208001
Dated: February 14, 2006.
Laura Rosenthal,
Associate Director for Management, National
Institute on Drug Abuse.
[FR Doc. E6–2824 Filed 2–28–06; 8:45 am]
BILLING CODE 4167–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SBIR Topic
216 Phase I/II ‘‘Fast Track Development of
Inhibitory Reagents for the Study of Protein
Function’’.
Date: March 28, 2006.
Time: 10:30 a.m. to 1 p.m.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Executive Plaza North, 6130 Executive
Boulevard, Conference Room J, Rockville,
MD 20892, (Telephone Conference Call).
Contact Person: Gerald G. Lovinger, PhD.,
Scientific Review Administrator, Special
Review and Logistics Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8101,
Bethesda, MD 20892–8329, (301) 496–7987,
lovingeg@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 21, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–1879 Filed 2–28–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Special Emphasis Panel, March
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 71, Number 40 (Wednesday, March 1, 2006)]
[Notices]
[Page 10540]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-1879]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel, SBIR Topic 216 Phase I/II ``Fast Track Development of
Inhibitory Reagents for the Study of Protein Function''.
Date: March 28, 2006.
Time: 10:30 a.m. to 1 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Executive Plaza North,
6130 Executive Boulevard, Conference Room J, Rockville, MD 20892,
(Telephone Conference Call).
Contact Person: Gerald G. Lovinger, PhD., Scientific Review
Administrator, Special Review and Logistics Branch, Division of
Extramural Activities, National Cancer Institute, 6116 Executive
Blvd., Room 8101, Bethesda, MD 20892-8329, (301) 496-7987,
lovingeg@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: February 21, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-1879 Filed 2-28-06; 8:45 am]
BILLING CODE 4140-01-M
